Mezzion Pharma Co.,Ltd. (KOSDAQ: 140410)
South Korea
· Delayed Price · Currency is KRW 31,750
-850 (-2.61%)
Dec 20, 2024, 9:00 AM KST
Mezzion Pharma Co.,Ltd. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 14,077 | 31,721 | 30,726 | 26,654 | 28,634 | 17,920 | Upgrade
|
| Revenue | 14,077 | 31,721 | 30,726 | 26,654 | 28,634 | 17,920 | Upgrade
|
| Revenue Growth (YoY) | -56.15% | 3.24% | 15.28% | -6.92% | 59.79% | -6.11% | Upgrade
|
| Cost of Revenue | 11,586 | 27,836 | 31,040 | 22,956 | 21,196 | 15,020 | Upgrade
|
| Gross Profit | 2,491 | 3,884 | -313.44 | 3,698 | 7,438 | 2,901 | Upgrade
|
| Selling, General & Admin | 14,552 | 16,142 | 19,510 | 17,283 | 12,857 | 14,393 | Upgrade
|
| Research & Development | 471.83 | 938.97 | 2,217 | 1,956 | 937.56 | 12,149 | Upgrade
|
| Operating Expenses | 16,078 | 18,373 | 23,018 | 20,496 | 14,969 | 27,383 | Upgrade
|
| Operating Income | -13,587 | -14,489 | -23,331 | -16,798 | -7,531 | -24,483 | Upgrade
|
| Interest Expense | -350.79 | -315.46 | -423.44 | -323.41 | -320.21 | -317.84 | Upgrade
|
| Interest & Investment Income | 1,640 | 1,477 | 763.35 | 306.23 | 357.47 | 852.34 | Upgrade
|
| Currency Exchange Gain (Loss) | -1,622 | 996.94 | 3,177 | 3,700 | -2,460 | 612.75 | Upgrade
|
| Other Non Operating Income (Expenses) | 346.78 | -157.21 | -1,410 | 90.67 | 57.43 | 1,043 | Upgrade
|
| EBT Excluding Unusual Items | -13,574 | -12,488 | -21,225 | -13,025 | -9,895 | -22,292 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 26.76 | 14.25 | Upgrade
|
| Gain (Loss) on Sale of Assets | -54.52 | 7.35 | 8.99 | -1.08 | -23.92 | - | Upgrade
|
| Asset Writedown | - | - | -14,694 | - | -2,944 | - | Upgrade
|
| Pretax Income | -13,628 | -12,480 | -35,910 | -13,026 | -12,836 | -22,278 | Upgrade
|
| Income Tax Expense | 594.75 | 248.07 | 388.23 | 577.06 | 1,036 | 1,023 | Upgrade
|
| Earnings From Continuing Operations | -14,223 | -12,728 | -36,298 | -13,603 | -13,873 | -23,301 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | 43.53 | 50.02 | Upgrade
|
| Net Income | -14,223 | -12,728 | -36,298 | -13,603 | -13,829 | -23,251 | Upgrade
|
| Net Income to Common | -14,223 | -12,728 | -36,298 | -13,603 | -13,829 | -23,251 | Upgrade
|
| Shares Outstanding (Basic) | 30 | 28 | 27 | 27 | 26 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 28 | 27 | 27 | 26 | 26 | Upgrade
|
| Shares Change (YoY) | 8.37% | 5.63% | 0.17% | 2.63% | 0.11% | 4.24% | Upgrade
|
| EPS (Basic) | -477.55 | -450.74 | -1357.81 | -509.70 | -531.83 | -895.16 | Upgrade
|
| EPS (Diluted) | -478.51 | -451.00 | -1358.00 | -510.00 | -531.99 | -895.16 | Upgrade
|
| Free Cash Flow | -19,931 | -11,553 | -12,842 | -15,429 | -8,151 | -21,978 | Upgrade
|
| Free Cash Flow Per Share | -669.19 | -409.10 | -480.39 | -578.14 | -313.46 | -846.15 | Upgrade
|
| Gross Margin | 17.69% | 12.25% | -1.02% | 13.88% | 25.98% | 16.19% | Upgrade
|
| Operating Margin | -96.52% | -45.68% | -75.93% | -63.02% | -26.30% | -136.62% | Upgrade
|
| Profit Margin | -101.04% | -40.13% | -118.13% | -51.03% | -48.30% | -129.75% | Upgrade
|
| Free Cash Flow Margin | -141.58% | -36.42% | -41.80% | -57.89% | -28.47% | -122.64% | Upgrade
|
| EBITDA | -12,471 | -12,942 | -21,673 | -15,212 | -6,098 | -23,151 | Upgrade
|
| EBITDA Margin | -88.60% | -40.80% | -70.54% | -57.07% | -21.30% | -129.19% | Upgrade
|
| D&A For EBITDA | 1,115 | 1,546 | 1,658 | 1,586 | 1,432 | 1,332 | Upgrade
|
| EBIT | -13,587 | -14,489 | -23,331 | -16,798 | -7,531 | -24,483 | Upgrade
|
| EBIT Margin | -96.52% | -45.67% | -75.93% | -63.02% | -26.30% | -136.62% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.